Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KUND:M.
Thanks Doc328.
Thanks falconer:
Will it matter if patients are now living normal lives after being treated with A2-73?
falconer, thanks for your read. This was a new path (I thought) for BIIB and they used the "Precision Medicine" word. IMO, it is pretty hard to figure them out but for sure they do have a big investment PR budget . Thanks again.
Biostockclub; exceptional information as usual. Will study and get back w/any follow up questions. BR
Falconer, Biostockclub, doc328, others. Any thoughts or comments on this PR from BIIB today. Curious if you see any possible ref link to A2-73 research @BIIB . IMHO this is the type of work I would have expected w/PM methods-protocols, positive links to measurable test criteria. TIA
https://finance.yahoo.com/news/biogen-advances-research-improve-outcomes-113000794.html
Biomarker Could Guide MS Treatment Decisions
Biogen is engaged in research to evaluate sNfL, a protein that reflects neuronal damage and is elevated in the blood of people with MS, as a biomarker of disease activity. Results from a retrospective analysis of more than 1,000 patients support the clinical relevance of sNfL levels in the blood to predict disease severity and monitor treatment response in MS patients. Data indicate that sNfL levels above a certain threshold are associated with ongoing disease activity and negative clinical and radiologic outcomes, such as more disability progression and brain atrophy. Researchers also found that introducing disease-modifying therapies significantly reduced sNfL levels, and greater reduction was associated with better treatment outcomes.
“Our research suggests that serum neurofilament light is a promising biomarker that may predict a person’s disease course and help guide treatment decisions in MS,” said Peter Calabresi, M.D., director of the division of neuroimmunology and neuro-infectious diseases at the Johns Hopkins University School of Medicine. “These findings support sNfL as a clinically useful biomarker to help predict whether a person with MS is likely to have a fast-progressing or milder disease course. They also open the possibility of using a simple blood test to monitor whether a patient is responding to a specific treatment. The strong predictive power of sNfL may ultimately provide physicians with additional information beyond what is currently measured by MRIs to help guide treatment decisions.”
Looks like the Precision Medicine path will change how much BIIB makes on MS. Doing retrospective analysis is a certain sign of RWE at work.
Xena:[quoteAssociate Professor Stephen Macfarlane, Head of HammondCare Clinical Services, is the principal investigator of the trial.
“We’re still not sure what causes Alzheimer’s disease, but the prevailing theory is the brain is damaged by a build-up of toxic proteins,” A/Prof Macfarlane said.
“There have been many failed trials attempting to remove these proteins or prevent them being produced.
“The theory behind Anavex 2-73 is that it targets a receptor that, when activated, leads to the removal of these abnormal proteins from brain cells.”
The Phase II trial of the drug, featuring 32 patients across Victoria, found their mini mental state exam (MMSE) score remained essentially unchanged after 18 months. The degree of decline expected in a person at a similar stage of Alzheimer’s disease is about two MMSE points per year.
Six of the patients also improved their MMSE scores significantly – an unprecedented outcome in Alzheimer’s treatment. This trial was extended from an initial six months to five years on the basis of the strength of the results and at the request of trial participants and their carers. ][/quote]
flashing back to the outputs from the BIIB PR team where the message has been …"still going downhill but at a slower pace"...my para...Cannot help but think what the BIIB PR team would do with the Dr. Mc F. quote above.
Questions? Will NYY sell all their goonies and move on now that the BOS. RED SOX destroyed them?
And, will this be the day the AVXL retail holders are rewarded?
BIIB just blinked again. They do this b/c it works for them, AD Patients...not so much. Musashi says..."When being pursued by a powerful and confident opponent you must stop and hit them between the eyes as hard as you can." The CTAD show is important for BIIB and everyone else. We should expect more of the same, IMO.
https://finance.yahoo.com/m/2ed8afcb-d672-315c-8442-54b00b74f957/a-look-at-biogen’s.html
dia76ca.Thank you for the response.
M. did say during this recent Cantor presentation that an IND for RS had been submitted. He did not say when or make any other qualifying comment. It sounded clear enough although he did not say when and no one asked.
https://seekingalpha.com/article/4186314-biogen-alzheimers-disease-reasons-caution
REALLY?
Nice:
Worry me this??
If all the knowledge in the known world on AD is compressed into one AVXL 15 min. slide presentation at CTAD in Late October 2018, THEN WHAT? If all the Amyloid Thesis trials are dead and done (excluding BIIB) Is it game over for AD treatment unless A2-73 is promising as we expect? Have all the worlds medical research people and advocates painted them selves into a corner? P.M. is the only game in town, but it takes time to retool everyone. If we are due for only another pump-dump SP cycle then the forecasted largest medical issue on the planet is going to be nasty.
We are way overdue for some real AD treatment news and most of the ammo is gone, IMO.
JonJon-Biostocker…anyone.do you see what I see here with BIIB or am I imagining this? This looks like a PM thought vs old school. Is this a form of blinking? In any case the PM process is doing it's influence thing, IMO.
https://finance.yahoo.com/news/spinraza-nusinersen-data-presented-annual-113000069.html
Looks like BIIB has played a Precision Medicine hand and got results that make a difference. The kids win. Good move, see n=x as possible example proof by science and knowledge vs proof by trial.
jonjones:
https://www.fda.gov/Training/GuidanceWebinars/ucm367786.htm
see numerous posts from Xena on this topic, DZ for example